HCA Healthcare, Inc. (NYSE:HCA) Position Increased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in HCA Healthcare, Inc. (NYSE:HCA) by 2.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 1,487,367 shares of the company’s stock after acquiring an additional 41,190 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in HCA Healthcare were worth $604,511,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in HCA. Terra Nova Asset Management LLC raised its stake in HCA Healthcare by 0.3% during the 3rd quarter. Terra Nova Asset Management LLC now owns 8,112 shares of the company’s stock valued at $3,297,000 after acquiring an additional 26 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its stake in HCA Healthcare by 7.4% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 421 shares of the company’s stock valued at $171,000 after acquiring an additional 29 shares in the last quarter. Waldron Private Wealth LLC raised its stake in HCA Healthcare by 1.8% during the 3rd quarter. Waldron Private Wealth LLC now owns 1,681 shares of the company’s stock valued at $683,000 after acquiring an additional 29 shares in the last quarter. Brookstone Capital Management raised its stake in shares of HCA Healthcare by 0.7% in the 3rd quarter. Brookstone Capital Management now owns 4,065 shares of the company’s stock worth $1,652,000 after buying an additional 30 shares in the last quarter. Finally, UMB Bank n.a. raised its stake in shares of HCA Healthcare by 2.4% in the 3rd quarter. UMB Bank n.a. now owns 1,301 shares of the company’s stock worth $529,000 after buying an additional 30 shares in the last quarter. Institutional investors own 62.73% of the company’s stock.

Insider Activity at HCA Healthcare

In other HCA Healthcare news, EVP Michael S. Cuffe sold 8,358 shares of the company’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $385.42, for a total transaction of $3,221,340.36. Following the completion of the sale, the executive vice president now owns 29,678 shares of the company’s stock, valued at $11,438,494.76. This represents a 21.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Erol R. Akdamar sold 2,900 shares of the company’s stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $353.00, for a total transaction of $1,023,700.00. Following the sale, the insider now directly owns 6,843 shares of the company’s stock, valued at approximately $2,415,579. This represents a 29.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 15,155 shares of company stock valued at $5,608,990. Insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on HCA shares. Barclays dropped their price objective on HCA Healthcare from $396.00 to $392.00 and set an “overweight” rating on the stock in a research note on Friday, November 8th. Cantor Fitzgerald reissued an “overweight” rating and issued a $392.00 price objective on shares of HCA Healthcare in a research note on Tuesday, October 1st. Oppenheimer boosted their price objective on HCA Healthcare from $390.00 to $400.00 and gave the stock an “outperform” rating in a research note on Monday, October 28th. Truist Financial lifted their target price on HCA Healthcare from $390.00 to $430.00 and gave the stock a “buy” rating in a report on Monday, August 19th. Finally, UBS Group lifted their target price on HCA Healthcare from $405.00 to $438.00 and gave the stock a “buy” rating in a report on Wednesday, August 14th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, twelve have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $380.29.

HCA Healthcare Price Performance

HCA opened at $325.47 on Friday. The stock has a market cap of $82.44 billion, a price-to-earnings ratio of 14.61, a PEG ratio of 1.25 and a beta of 1.68. HCA Healthcare, Inc. has a 1 year low of $245.84 and a 1 year high of $417.14. The company has a current ratio of 1.12, a quick ratio of 1.00 and a debt-to-equity ratio of 48.71. The stock has a fifty day moving average price of $373.42 and a 200 day moving average price of $358.28.

HCA Healthcare Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 27th. Investors of record on Friday, December 13th will be given a dividend of $0.66 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $2.64 dividend on an annualized basis and a yield of 0.81%. HCA Healthcare’s payout ratio is 11.85%.

About HCA Healthcare

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.